Tc Biopharm Holdings Stock Revenue
| TCBP Stock | USD 0.64 0.02 3.03% |
TC BioPharm Holdings fundamentals help investors to digest information that contributes to TC BioPharm's financial success or failures. It also enables traders to predict the movement of TCBP Stock. The fundamental analysis module provides a way to measure TC BioPharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to TC BioPharm stock.
| Last Reported | Projected for Next Year |
TCBP | Revenue |
TC BioPharm Holdings Company Revenue Analysis
TC BioPharm's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of TCBP
Projected quarterly revenue analysis of TC BioPharm Holdings provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of TC BioPharm match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in TC BioPharm's stock price.
TCBP Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for TC BioPharm is extremely important. It helps to project a fair market value of TCBP Stock properly, considering its historical fundamentals such as Revenue. Since TC BioPharm's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of TC BioPharm's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of TC BioPharm's interrelated accounts and indicators.
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
TCBP Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, TC BioPharm Holdings reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
TCBP Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses TC BioPharm's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of TC BioPharm could also be used in its relative valuation, which is a method of valuing TC BioPharm by comparing valuation metrics of similar companies.TC BioPharm is currently under evaluation in revenue category among its peers.
TC BioPharm Institutional Holders
Institutional Holdings refers to the ownership stake in TC BioPharm that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of TC BioPharm's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing TC BioPharm's value.| Shares | Csenge Advisory Group, Llc | 2024-06-30 | 12 K | Citadel Advisors Llc | 2024-06-30 | 0.0 | Rhumbline Advisers | 2024-06-30 | 844 | Signaturefd, Llc | 2024-09-30 | 492 | Harbour Investments, Inc. | 2024-09-30 | 236 | New England Capital Financial Advisors Llc | 2024-09-30 | 201 | Sanctuary Wealth Management, Llc | 2024-09-30 | 12.0 | Headlands Technologies Llc | 2024-06-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Virtu Financial Llc | 2024-06-30 | 0.0 | Platform Technology Partners | 2024-09-30 | 0.0 |
TCBP Fundamentals
| Return On Equity | -12.17 | ||||
| Return On Asset | -1.09 | ||||
| Current Valuation | 1.32 M | ||||
| Shares Outstanding | 572.02 K | ||||
| Shares Owned By Institutions | 1.76 % | ||||
| Number Of Shares Shorted | 64.93 K | ||||
| Price To Book | 0.28 X | ||||
| Price To Sales | 0.51 X | ||||
| Gross Profit | 3.84 M | ||||
| EBITDA | (13.61 M) | ||||
| Net Income | (5.91 M) | ||||
| Cash And Equivalents | 1.57 M | ||||
| Cash Per Share | 0.08 X | ||||
| Total Debt | 1.8 M | ||||
| Current Ratio | 0.19 X | ||||
| Book Value Per Share | 3.38 X | ||||
| Cash Flow From Operations | (10.54 M) | ||||
| Short Ratio | 0.05 X | ||||
| Earnings Per Share | (192.95) X | ||||
| Target Price | 140.0 | ||||
| Number Of Employees | 41 | ||||
| Beta | 0.25 | ||||
| Market Capitalization | 360.37 K | ||||
| Total Asset | 8.93 M | ||||
| Retained Earnings | (38.84 M) | ||||
| Working Capital | 950.33 K | ||||
| Net Asset | 8.93 M |
About TC BioPharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze TC BioPharm Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TC BioPharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TC BioPharm Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with TC BioPharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if TC BioPharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TC BioPharm will appreciate offsetting losses from the drop in the long position's value.Moving together with TCBP Stock
| 0.67 | A | Agilent Technologies Sell-off Trend | PairCorr |
| 0.85 | ME | 23Andme Holding | PairCorr |
| 0.76 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against TCBP Stock
| 0.67 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.46 | KZR | Kezar Life Sciences | PairCorr |
| 0.41 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.37 | KEP | Korea Electric Power | PairCorr |
The ability to find closely correlated positions to TC BioPharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace TC BioPharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back TC BioPharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling TC BioPharm Holdings to buy it.
The correlation of TC BioPharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as TC BioPharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if TC BioPharm Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for TC BioPharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for TCBP Stock Analysis
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.